What is the current stock price of Aptorum Group Limited (APM)?

As of the latest market data, Aptorum Group Limited (APM) is trading at $0.84. The stock has seen a loss of -0.60% today.

Does Aptorum Group Limited (APM) pay a dividend?

Based on current data, Aptorum Group Limited does not have a confirmed active dividend policy.

What is the market cap of Aptorum Group Limited?

The current market capitalization of Aptorum Group Limited (APM) is approximately unavailable.

APM

Aptorum Group Limited·Healthcare

0.84

0.600%(−0.01)

Close Price

0.87

3.018%(+0.03)

Pre-Market

Last Updated: — ET

52W L: $0.6552W H: $4.47

APM NEWS

seekingalpha.com

May 13

Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript

defenseworld.net

Apr 16

Head-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)

Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta

defenseworld.net

Apr 14

Aptorum Group Limited (NASDAQ:APM) Short Interest Up 41.4% in March

Aptorum Group Limited (NASDAQ: APM - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 12,292 shares, a growth of 41.4% from the March 15th total of 8,693 shares. Based on an average trading volume of 145,672 shares, the short-interest ratio

defenseworld.net

Apr 7

Prelude Therapeutics (NASDAQ:PRLD) vs. Aptorum Group (NASDAQ:APM) Critical Review

Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Risk and Volatility Aptorum Group has a

defenseworld.net

Mar 27

Andean Precious Metals Q4 Earnings Call Highlights

Andean Precious Metals (TSE: APM) used its fourth-quarter and year-end earnings call to highlight what management described as a "step change" in 2025 results, driven by record financial performance, strong free cash flow, and a significantly strengthened balance sheet. Executives pointed to contributions from both the San Bartolomé silver operation and the Golden Queen gold operation,

seekingalpha.com

Mar 25

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript

Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-12-18

Beta

0.09

Websitewww.aptorumgroup.com↗